Surgical Outcomes After Risk-Reducing Mastectomy Among <i>BRCA1</i> and <i>BRCA2</i> Carriers
Rebecca Wiberg(Umeå University), Ylva A. Karlsson(Swedish Institute), Christina Edwinsdotter Ardnor(Swedish Institute), Annika Idahl(Umeå University), Hans Ehrencrona(Lund University), M Sund(University of Helsinki), Ekaterina Kuchinskaya(Linköping University Hospital), Barbro Numan Hellquist(Umeå University), Anna Öfverholm(Swedish Institute), Maria Mani(Uppsala University), Åke Borg(Swedish Institute), N. Loman(Lund University), Per Karlsson(University of Gothenburg), Anna von Wachenfeldt(Karolinska Institutet), Signe Hägglund(Umeå University), Svetlana Bajalica-Lagercrantz(Karolinska University Hospital), Johanna Rantala(Swedish Institute), Swedish BRCA Study Group, Anna Rosén(Unknown)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium
|Journal of Clinical Oncology|2016|517
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|507
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i>
|JNCI Journal of the National Cancer Institute|2020|163